Halozyme Therapeutics, Inc.
HALO· Nasdaq
HALOHalozyme Therapeutics, Inc.
Filed Feb 28, 2014 · 10-K · 59 days after period end · 0001159036-14-000033
| Metric | Q4 2013 | Q4 2012 | Q4 2011 | Q4 2010dderived from reported figures |
|---|---|---|---|---|
| Revenue | $12.50M | $21.79M | $2.41M | — |
| Net Income | -$21.99M | -$4.41M | -$18.42M | — |
| EPS Diluted | -$0.19 | -$0.04 | -$0.18 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
ended Dec 31, 2013 · filed Feb 28, 2014 · 59 d after period end
